George Kim
Overview
Explore the profile of George Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Parascandola S, Horsey M, Hota S, Sparks A, Tampo M, Kim G, et al.
J Robot Surg
. 2020 Oct;
15(5):701-710.
PMID: 33104963
Historically, T4 tumors of the colon have been a contraindication to minimally invasive resection. The purpose of this study was to conduct a National Cancer Database analysis to compare the...
12.
Lee C, Kim G, Chou Y, Musico B, Gao M, An K, et al.
Sci Adv
. 2020 Sep;
6(37).
PMID: 32917694
Single-phase solid-solution refractory high-entropy alloys (HEAs) show remarkable mechanical properties, such as their high yield strength and substantial softening resistance at elevated temperatures. Hence, the in-depth study of the deformation...
13.
Koeller J, Surinach A, Arikian S, Zivkovic M, Janeczko P, Cockrum P, et al.
Ther Adv Med Oncol
. 2020 Sep;
12:1758835920944052.
PMID: 32874209
There are questions surrounding the real-world effectiveness of chemotherapeutic treatments for pancreatic ductal adenocarcinoma. This literature review compared the clinical characteristics and outcomes of available real-world evidence (RWE) for liposomal...
14.
Carr R, Duma N, McCleary-Wheeler A, Almada L, Marks D, Graham R, et al.
Pancreatology
. 2020 Aug;
20(6):1115-1122.
PMID: 32778368
Background/objectives: Preclinical data indicated a functional and molecular interaction between Hedgehog (HH)/GLI and PI3K-AKT-mTOR pathways promoting pancreatic ductal adenocarcinoma (PDAC). A phase I study was conducted of Vismodegib and Sirolimus...
15.
Parascandola S, Hota S, Sparks A, Boulos S, Cavallo K, Kim G, et al.
Surg Endosc
. 2020 Jul;
35(6):3154-3165.
PMID: 32601761
Background: This study examined utilization and conversion rates for robotic and laparoscopic approaches to non-metastatic rectal cancer. Secondary aims were to examine short- and long-term outcomes of patients who underwent...
16.
Chiorean E, Cheung W, Giordano G, Kim G, Al-Batran S
Ther Adv Med Oncol
. 2019 Jun;
11:1758835919850367.
PMID: 31205510
Background: No clinical trial has directly compared nab-paclitaxel/gemcitabine (nab-P/G) with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced pancreatic cancer (mPC or aPC). We conducted a systematic review of real-world studies comparing...
17.
Downar J, Green S, Radhakrishnan A, Wales J, Kim G, Seccareccia D, et al.
CMAJ Open
. 2018 Dec;
6(4):E657-E663.
PMID: 30578274
Background: In jurisdictions where medical aid in dying (MAiD) is legal, there is an obligation to ensure the competence of those who assess eligibility and provide MAiD to patients. Entrustable...
18.
Kim G, Meschel S, Nash P, Chen W
Sci Data
. 2017 Oct;
4:170162.
PMID: 29064466
The standard enthalpy of formation of a compound is the energy associated with the reaction to form the compound from its component elements. The standard enthalpy of formation is a...
19.
Kim G
Cancer Manag Res
. 2017 Mar;
9:85-96.
PMID: 28356771
Background: Nanoparticle albumin-bound paclitaxel (-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). A large...
20.